The 5 Pack of BTNX Rapid Response® antigen tests is the perfect screening tool for COVID-19. Put your mind at ease with a 5-pack of BTNX Rapid Response® COVID-19 Antigen Rapid Test Device. It is an efficient, accurate, and reliable method of testing. It is easy to use and delivers results within 15 minutes! The BTNX Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretion samples. Package Contents: 5 Test cassettes 5 Individually packed swabs 5 individually packed buffers 5 tubes and nozzles 1 Tube stand 1 Product insert Intended Use The Rapid Response(TM) COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection, when tested twice over two (or three) days with at least 24 hours (and no more than 36 hours) between tests. This test is authorized for use at the Point of Care i.e., in patient care setting. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigens are generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed witha molecular assay, if necessary, for patient management. The Rapid Response(TM) COVID-19 Antigen Rapid Test Device is intended for use by trained laboratory personnel or health care professionals. By purchasing this product, you agree to follow the manufacturer’s intended use for this product. Weight 0.05 lbs Test Technology Antigen Diagnostic Sensitivity 78.6% - 96.2% Diagnostic Specificity 96.5% - 100% Shelf Life (expiration) 12-18 months Storage Temperature 2-30°C/36-86°F Time to Result 15 minutes Sample Collection Shallow nasal

The Roche SARS-CoV-2 Rapid Antigen Test is a reliable, rapid chromatographic immunoassay for the qualitative detection of specific antigens of SARS-CoV-2 present in the human nasopharynx. This test is an aid in detecting antigens from the SARS-CoV-2 virus in individuals suspected of COVID-19. This product is strictly intended for professional use in by trained individuals.  The kit is ready for use and contains all equipment needed to perform a test. The following components are needed for a test and included in the kit: Test device (individually in a foil pouch with desiccant) Extraction buffer tube Nozzle cap Sterile swabd Film (can be attached to the test device when performing outdoor testing) Instructions for use Quick Reference Guide Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worker. By purchasing this product, you agree to follow the manufacturer’s intended use. Note: Images are for reference only. Actual product packaging may vary.

The Rapid Response™ antigen test device is the perfect screening tool for organizations that want to try to protect their workplace from the risk of COVID-19 lockdowns. Used as part of a comprehensive rapid testing program for COVID-19, the BTNX nasal device offers fast, easy-to-use, and reliable screening. Testing all staff 1-2 times/week will help detect the virus early and decrease the likelihood of spreading COVID-19. Rapid Response® COVID-19 Antigen Rapid Test Device. It is an efficient, accurate, and reliable method of testing that can be used by any healthcare professional. It is easy to use and delivers results within 15 minutes! The BTNX Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretion samples. Intended Use The Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset. This test is authorized for use at the Point ofCare i.e., in patient care settings. Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigens are generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patientmanagement. The Rapid Response™ COVID-19 Antigen Rapid Test Device is intended for use by trained laboratory personnel or health care professionals. By purchasing this product, you agree to follow the manufacturer’s intended use.   Test Technology Antigen Diagnostic Sensitivity 78.6% - 96.2% Diagnostic Specificity 96.5% - 100% Shelf Life (expiration) 6-18 months Storage Temperature 2-30°C/36-86°F Time to Result 15 minutes Sample Collection Shallow nasal